# Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis

> **NCT04142749** · PHASE3 · COMPLETED · sponsor: **PharmaKing** · enrollment: 146 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Oltipraz
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04142749
- **Lead sponsor:** PharmaKing
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-15
- **Primary completion:** 2022-09-02
- **Final completion:** 2022-09-26
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2022-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04142749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04142749, "Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04142749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*